Comprehensive Evaluation of SIRT1 as a Therapeutic Target in Metastatic Ovarian Cancer and Multimodel Assessment of its Inhibitor
Journal of Current Oncological Trends · 2026-01 · 3 (1) · 27-44
DOI: 10.4103/jcot.jcot_7_26 ↗At a glance
Journal article in Journal of Current Oncological Trends, published online on 2026-07-31. Written by Sraddhya Roy and 7 co-authors. 49 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
The menace caused by ovarian cancer (OvCa) is developing into an alarming situation globally because of its higher incidence and mortality rates. Despite technological and therapeutic advances, there is an emergency to identify a potent molecular target to combat the disease.
Aim
In this study, we investigated sirtuin 1 (SIRT1) as a potential target and demonstrated the therapeutic importance of inhibiting SIRT1. Materials and Methods: Publicly available datasets were analyzed to evaluate SIRT1 genetic alterations, expression, and clinical significance in OvCa. Metascape and Gene Set Cancer Analysis were performed to investigate the involvement of SIRT1 in EMT and PI3K/AKT signaling. Molinspiration and the pkCSM server were implemented to study drug likeness and ADME/T properties of selected ligands, followed by MD simulation of target-ligand interactions. Experimental validations examined the effects of SIRT1 Inhibitor III on OvCa migration and progression.
Results
SIRT1 genetic alterations are higher in OvCa cases and in TP53 mutant samples. SIRT1 expression was higher in OvCa tissues and adjacent normal tissues (N = 15). Functional analyses associated SIRT1 with EMT and PI3K/AKT signaling. SIRT1 Inhibitor III demonstrated the strongest binding affinity toward SIRT1, PI3K, and AKT compared with hyperforin and favorable pharmacokinetic properties, with stable protein-ligand interactions during MD simulations. Experimental validations in SKOV3 cells (IC 50 = 0.1606 μM) showed reduced cellular migration, and in C57BL/6 mice, reduced tumor progression was observed.
Conclusion
Collectively, in silico approaches and experimental validations revealed SIRT1 as a promising therapeutic target and the efficacy of SIRT1 Inhibitor III for OvCa progression.
Cite
APA
Roy, S., Maiti, K., Roy, A., Das, A., Bairagi, A., Vernekar, M., Chatterjee, N., & Ponnusamy, C. S. (2026). Comprehensive Evaluation of SIRT1 as a Therapeutic Target in Metastatic Ovarian Cancer and Multimodel Assessment of its Inhibitor. Journal of Current Oncological Trends, 3(1), 27-44. https://doi.org/10.4103/jcot.jcot_7_26
Vancouver
Roy S, Maiti K, Roy A, Das A, Bairagi A, Vernekar M, et al. Comprehensive Evaluation of SIRT1 as a Therapeutic Target in Metastatic Ovarian Cancer and Multimodel Assessment of its Inhibitor. Journal of Current Oncological Trends. 2026;3(1):27-44. doi:10.4103/jcot.jcot_7_26
BibTeX
@article{Roy2026,
author = {Roy, Sraddhya and Maiti, Koustav and Roy, Arundhati and Das, Ananya and Bairagi, Aparajita and Vernekar, Manisha and Chatterjee, Nabanita and Ponnusamy, Chandra Sekar},
title = {Comprehensive Evaluation of SIRT1 as a Therapeutic Target in Metastatic Ovarian Cancer and Multimodel Assessment of its Inhibitor},
journal = {Journal of Current Oncological Trends},
year = {2026},
volume = {3},
number = {1},
pages = {27--44},
doi = {10.4103/jcot.jcot_7_26}
}
EUVIMED